Clopidogrel Audit Vikas Jasoria December 2006. What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

Unstable angina and NSTEMI
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
National Service Frameworks Dr Stephen Newell February 2002.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Canadian Cardiovascular Society Antiplatelet Guidelines
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
CVD risk estimation and prevention: An overview of SIGN 97.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
Ischaemic Heart Disease for the GP Chris Tracey GPVTS.
Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.
Should we??. Aspirin is useful! It is widely used in secondary prevention It reduces the yearly risk of vascular events by about a quarter This corresponds.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Dr Avinash Haridas Pillai
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Combination Therapy in Acute Coronary Disease Elizabeth Gabrielle PA-S Lock Haven University February 2009.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
ANTIPLATELET TREATMENT IN PATIENTS WHO HAVE AN ISCHEMIC STROKE WHILE TAKING ASPIRIN Konstantinos Tziomalos, Stella D. Bouziana, Marianna Spanou, Stavroula.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Acute Coronary Syndromes in West Hertfordshire Masood Khan.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Carotid Disease – Stent vs Surgery vs Medical Therapy? Mehdi H. Shishehbor, DO, MPH, PhD Director, Endovascular Services Interventional Cardiology & Vascular.
Local Enhanced Service Care bundles Dr Andy Kilpatrick, Clinical Lead.
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Canadian Cardiovascular Society Antiplatelet Guidelines
Management of ST-Elevation Myocardial Infarction
Antiplatelet therapy for STEMI
Andre Lamy on behalf of the COMPASS Investigators
First time a CETP inhibitor shows reduction of serious CV events
Preventing Thrombotic Complications in ACS: State of the Art
Oral Anticoagulation and Preventing Stent Thrombosis
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
European Heart Association Journal 2007 April
NOACS: Emerging data in ACS/IHD
Five Things You Need to Know About Secondary Prevention Post-ACS
Preventive Angioplasty in Myocardial Infarction Trial
Factor Xa Inhibitors in PAD
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
What oral antiplatelet therapy would you choose?
Factor Xa Inhibitors in Coronary Artery Disease
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
2017/18 National Diabetes Audit Cambridgeshire and Peterborough CCG local summary Public Health Intelligence, Cambridgeshire and Peterborough : April 2019.
Section C: Clinical trial update: Oral antiplatelet therapy
Cardiovascular Epidemiology and Epidemiological Modelling
Dervin Ariansyah 1. Antiplatelet Therapy Aspirin Acetysalicylic Acid Ticlopidine Clopidogrel Prasugrel Thienopyridines Cilostazol Dipyridamole Novel Agents.
Presentation transcript:

Clopidogrel Audit Vikas Jasoria December 2006

What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting the binding of adenosine phosphate to its platelet receptor Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting the binding of adenosine phosphate to its platelet receptor IN SIMPLE TERMS IN SIMPLE TERMS Anti-platelet which works in a different way to aspirin Anti-platelet which works in a different way to aspirin

Why Clopidogrel? Increasing prescriptions Increasing prescriptions 2003: 2003: 2.1m prescriptions costing £87m 2.1m prescriptions costing £87m Increase of > 50% since 2002 Increase of > 50% since 2002 Length of course often not specified Length of course often not specified Patients on Clopidogrel indefinitely when may not need to be the case Patients on Clopidogrel indefinitely when may not need to be the case

Why Clopidogrel? Prescribers incentive scheme 2006/2007 Prescribers incentive scheme 2006/2007

In real terms….. 28 tablets cost £ tablets cost £ £ per patient per year (aspirin £ 10.44) £ per patient per year (aspirin £ 10.44) £ per year saving per patient!!!!!! £ per year saving per patient!!!!!! Stop giving BIG PHARMA money……. Stop giving BIG PHARMA money……. Use money for other health services…… Use money for other health services……

The Evidence Primary Prevention Primary Prevention CHARISMA trial CHARISMA trial Clopidogrel plus aspirin is no more effective than aspirin alone in preventing major cardiovascular events Clopidogrel plus aspirin is no more effective than aspirin alone in preventing major cardiovascular events

The Evidence Antithrombotic Trialists Collaboration (BMJ2002;324:71) Antithrombotic Trialists Collaboration (BMJ2002;324:71) Clopidogrel is an effective alternative if cannot take aspirin Clopidogrel is an effective alternative if cannot take aspirin

The Evidence Post MI/ACS: Post MI/ACS: CLARITY trial (NEJM2005:352;1179) & COMMIT study (Lancet2005:366;1667) CLARITY trial (NEJM2005:352;1179) & COMMIT study (Lancet2005:366;1667) Addition of clopidogrel to aspirin improves outcomes (Decreased mortality and CV complications) Addition of clopidogrel to aspirin improves outcomes (Decreased mortality and CV complications) No additional risk of bleeding when used in combination No additional risk of bleeding when used in combination Clopidogrel and aspirin should be used in standard treatment post MI, at least in short term Clopidogrel and aspirin should be used in standard treatment post MI, at least in short term

The Evidence NICE (NSTEMI): NICE (NSTEMI): Continue up to 12 months after most recent acute episode ACS Continue up to 12 months after most recent acute episode ACS Prescribers incentive scheme: Prescribers incentive scheme: Clopidogrel licenced for use in MI (STEMI) up to 35 days after the event Clopidogrel licenced for use in MI (STEMI) up to 35 days after the event  For cardiac event:  For cardiac event: No patient should be on clopidogrel for secondary prevention for > 1 year No patient should be on clopidogrel for secondary prevention for > 1 year

The Evidence JBS Guideline: JBS Guideline: IF ASPIRIN NOT TOLERATED: IF ASPIRIN NOT TOLERATED: Prescribe clopidogrel 75mg od for Prescribe clopidogrel 75mg od for Vascular disease Vascular disease Diabetes Diabetes Asymptomatic whose 10 year risk > 20% Asymptomatic whose 10 year risk > 20%

Indications – NO CVD & Aspirin intolerant Over 50 and > 20% Framingham 10 yr risk Over 50 and > 20% Framingham 10 yr risk Diabetics Diabetics Age 50 years or over Age 50 years or over Diabetes > 10 years Diabetes > 10 years Taking treatment for hypertension Taking treatment for hypertension Evidence of target organ damage Evidence of target organ damage All people with target organ damage from hypertension All people with target organ damage from hypertension AF AF

Indications – CVD & Aspirin intolerant CVD? CVD? With aspirin: With aspirin: Myocardial infarction, angina Myocardial infarction, angina If aspirin intolerant: If aspirin intolerant: Non-haemorrhagic cerebrovascular disease (not in AF) Non-haemorrhagic cerebrovascular disease (not in AF) Peripheral vascular disease Peripheral vascular disease Atherosclerotic renovascular disease Atherosclerotic renovascular disease

Criteria & Standards Patients on clopidogrel should have a valid clinical indication recorded Patients on clopidogrel should have a valid clinical indication recorded Standard: 90% Standard: 90% Patients prescribed clopidogrel as monotherapy should have documented contra-indication or intolerance of aspirin: Patients prescribed clopidogrel as monotherapy should have documented contra-indication or intolerance of aspirin: Standard: 90% Standard: 90% Patients on clopidogrel for ACS or MI are on clopidogrel for < 12 months after most recent acute cardiac episode Patients on clopidogrel for ACS or MI are on clopidogrel for < 12 months after most recent acute cardiac episode Standard: 90% Standard: 90%

Method Patients prescribed clopidogrel over last 90 days from 8 th November 2006 Patients prescribed clopidogrel over last 90 days from 8 th November 2006 Computer & paper notes (where indicated) Computer & paper notes (where indicated) Correspondence letters Correspondence letters Excel Spreadsheet Excel Spreadsheet  TIME CONSUMING !!!!!

RESULTS

Standard Met NO(NEARLY!!!)

Discussion Clinical indications? Clinical indications? “post hypotensive episode/migraine” “post hypotensive episode/migraine” Registered newly and was on clopidogrel before – no documentation as to why Registered newly and was on clopidogrel before – no documentation as to why ? Post valve replacement and warfarin intolerant ? Post valve replacement and warfarin intolerant Also on aspirin Also on aspirin January 2003: “Very keen to try clopidogrel for 1 month, has read about it in the paper”; “No more chest pain since starting clopidogrel” January 2003: “Very keen to try clopidogrel for 1 month, has read about it in the paper”; “No more chest pain since starting clopidogrel” No intolerance of aspirin noted No intolerance of aspirin noted

Discussion ?Swapping to clopidogrel because of need for NSAID and aspirin ?Swapping to clopidogrel because of need for NSAID and aspirin Started aspirin and clopidogrel 2002 after more TIAs. Started aspirin and clopidogrel 2002 after more TIAs. Advised by neuro then to cut out aspirin slowly and continue clopidogrel Advised by neuro then to cut out aspirin slowly and continue clopidogrel No intolerance of aspirin noted No intolerance of aspirin noted Evidence changes with time… we need to keep up Evidence changes with time… we need to keep up

FIX IT! Documentation, documentation, documentation Documentation, documentation, documentation Computer popup needed everytime Clopidogrel prescribed Computer popup needed everytime Clopidogrel prescribed “Is there a valid clinical indication documented in the notes” “Is there a valid clinical indication documented in the notes” Consider cost/benefit of patient requests for Clopidogrel when not indicated Consider cost/benefit of patient requests for Clopidogrel when not indicated Is it worth it? Is it worth it? Need to get a better history from new patients Need to get a better history from new patients Stop prescribing repeats and ask patients to come in for Stop prescribing repeats and ask patients to come in for medication review if needed Contacting individual GPs with their patients that need to be addressed Contacting individual GPs with their patients that need to be addressed

Standard Met NO

Discussion CVA/TIA who are on both aspirin and clopidogrel CVA/TIA who are on both aspirin and clopidogrel Old vs. new evidence Old vs. new evidence If aspirin is stopped then reason in notes needs to be more clearly documented If aspirin is stopped then reason in notes needs to be more clearly documented Patient awaiting angio after trop negative CP ?likely diagnosis stable angina but not aspirin intolerant Patient awaiting angio after trop negative CP ?likely diagnosis stable angina but not aspirin intolerant

FIX IT! Contact individual GPs Contact individual GPs If no intolerance of aspirin then stop Clopidogrel and change to aspirin If no intolerance of aspirin then stop Clopidogrel and change to aspirin ? Write to patients ? ? Write to patients ?

Standard Met NO (NEARLY!!!)

NOTE!!!! Excluded in results those that had cardiac event and stenting Excluded in results those that had cardiac event and stenting Controversial as to length of treatment of clopidogrel post stent Controversial as to length of treatment of clopidogrel post stent Numbers are low! Numbers are low!

Discussion Patient had NSTEMI November 2005 on discharge summary says "review in clinc" but no evidence of formal review note Patient had NSTEMI November 2005 on discharge summary says "review in clinc" but no evidence of formal review note

FIX IT! Contact GP involved Contact GP involved Consider stopping clopidogrel as > 1 year post MI Consider stopping clopidogrel as > 1 year post MI Set computer reminder to prompt if > 1 year post most recent cardiac event Set computer reminder to prompt if > 1 year post most recent cardiac event

CONCLUSIONS

Conclusions Old evidence vs. New evidence Old evidence vs. New evidence MEDICATION REVIEWS IMPORTANT MEDICATION REVIEWS IMPORTANT Documentation, documentation…….. Documentation, documentation…….. Not far from standards in 2/3 Not far from standards in 2/3 Need to address Clopidogrel monotherapy group Need to address Clopidogrel monotherapy group Solutions involve contacting individuals and making changes Solutions involve contacting individuals and making changes Difficult audit – which one for submission if any? Difficult audit – which one for submission if any? Re-audit in April 2007 Re-audit in April 2007

Thank You